Combination therapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your colorectal cancer must be a specific type called MSS (microsatellite stable), and you must have a special test result called MCRIH.
- Your cancer must have spread to other parts of the body and cannot be removed by surgery.
- You should be able to take care of yourself and be able to carry out light activities (ECOG 0-1).
- You must not have had immunotherapy (like checkpoint inhibitors) before.
- You must be willing to use contraception during the study if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.